Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials.
Abeline R WatkinsNicholas FialkaRyaan El-AndariJimmy Jh KangSabin J BozsoJeevan NagendranPublished in: Future cardiology (2023)
Aim: To determine if glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can benefit patients receiving coronary artery bypass graft (CABG), GLP-1 RAs administration alongside standard insulin was compared with perioperative insulin alone. Materials & methods: All articles from Pubmed and Scopus databases that compared GLP-1 RA administration to insulin alone during CABG were included for meta-analysis. Short-term postoperative outcomes were analyzed between groups. Results: Average postoperative blood glucose levels significantly favored GLP-1 RA with a mean difference of -0.72 (p < 0.001). No other variables were significantly different between GLP-1 RA and insulin alone. Conclusion: GLP-1 RA is a safe option for perioperative care of CABG patients that can potentially improve postoperative outcomes of CABG patients by improving glycemic control and reducing hyperglycemic episodes.
Keyphrases
- glycemic control
- coronary artery bypass grafting
- blood glucose
- type diabetes
- coronary artery bypass
- patients undergoing
- percutaneous coronary intervention
- end stage renal disease
- rheumatoid arthritis
- coronary artery disease
- ejection fraction
- disease activity
- newly diagnosed
- healthcare
- systematic review
- prognostic factors
- weight loss
- chronic kidney disease
- peritoneal dialysis
- ankylosing spondylitis
- systemic lupus erythematosus
- randomized controlled trial
- machine learning
- blood pressure
- clinical trial
- interstitial lung disease
- big data
- double blind
- quality improvement
- adipose tissue
- patient reported outcomes
- skeletal muscle
- idiopathic pulmonary fibrosis
- health insurance